MNMD

MNMD

USD

Mind Medicine (MindMed) Inc. Common Shares

$12.000-0.100 (-0.826%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$12.100

Máximo

$12.530

Mínimo

$11.880

Volume

2.12M

Fundamentos da empresa

Capitalização de mercado

1.2B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

1.69M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $4.7Atual $12.000Máximo $14.43

Notícias relacionadas

BusinessWire

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing

Ver mais
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
BusinessWire

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing

Ver mais
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
BusinessWire

MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance

Ver mais
MindMed Announces New Employee Inducement Grant
Analyst Upgrades

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position.

Ver mais
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression